Significance of serum S‐100B in melanoma patients before and after sentinel node biopsy
Authors:
- Léonie H.M. SmitLSLéonie H.M. Smit
- Bin B.R. KroonBKBin B.R. Kroon
- 20 April 2005
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 90 (2) , 66-69
Abstract
Background and Objectives: The clinical utility of the tumor marker serum S‐100B has been described in determining prognosis, for early diagnosis of recurrence and for disease monitoring in melanoma patients. Sentinel node biopsy is increasingly used as staging procedure for patients with clinically localized melanoma. The aim of this study was to determine the value of serum S‐100B in melanoma patients before and after sentinel lymph node biopsy.Methods: S‐100B values were measured prior to sentinel node biopsy in 89 patients and during follow‐up (median 41 months; range 7–73 months) in 88 patients. The detection limit is ≤0.08 μg/L. In our laboratory levels of 0.16 μg/L and above are classified as increased.Results: Twenty‐four patients had tumor‐positive sentinel nodes, 65 had tumor‐free sentinel nodes. The median S‐100B value prior to the operation was ≤0.08 μg/L for all patients. Sensitivity and specificity of S‐100B to predict the tumor‐status of the sentinel node were 13% and 98%, respectively. Eighteen patients developed a melanoma‐related recurrence. Sensitivity for early diagnosis of recurrence was 55% and 33%, respectively for patients with a positive versus a negative sentinel node. Specificity was 100% in both patient groups.Conclusions: S‐100B is not useful in predicting the tumor‐status of the sentinel node, and questionable for early diagnosis of recurrence afterwards. Elevation of serum S‐100B is highly specific for melanoma recurrence. J. Surg. Oncol. 2005;90:66–69.Keywords
This publication has 14 references indexed in Scilit:
- Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanomaBritish Journal of Dermatology, 2002
- Sensitivity of sentinel node biopsy in melanomaJournal of Surgical Oncology, 2001
- Serum S-100B Protein as a Prognostic Marker in Malignant Cutaneous MelanomaJournal of Clinical Oncology, 2001
- Serological markers for melanomaBritish Journal of Dermatology, 2000
- Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanomaBritish Journal of Dermatology, 2000
- S-100 protein in peripheral blood: A marker for melanoma metastasesJournal of the American Academy of Dermatology, 1999
- Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma PatientsJournal of Clinical Oncology, 1999
- Principles and guidelines for surgeons: management of cutaneous malignant melanomaEuropean Journal of Surgical Oncology, 1997
- Clinical significance of serum S100 in metastatic malignant melanomaEuropean Journal of Cancer, 1995
- A soluble protein characteristic of the nervous systemBiochemical and Biophysical Research Communications, 1965